AI Stock Memo: SMMT - Summit Therapeutics - RankAlpha

SMMT

Rating neutralTentativeAI Memo

Summit Therapeutics

As of 2026-05-04/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

HARMONi-3 squamous final PFS in 2H 2026 after interim continuation • 2026-09-30

Expected move: +9%

Biggest risk

The same update also showed the interim HARMONi-3 look was not the breakthrough event some investors may have wanted, with the study simply continuing as planned. Cash and short-term investments fell to $598.7 million from $713.4 million at year-end, while non-GAAP operating expenses rose to $122.4 million, reinforcing that the stock is still highly dependent on future data and regulatory success rather than current operating leverage [#8-K-2026-04-30].

Invalidation

Break below $9 or thesis failure.

What would change my mind?

The April 30 company update kept the core ivonescimab timeline intact: ASCO OS data on May 31, HARMONi-3 squamous final PFS still in 2H 2026, and the November 14, 2026 PDUFA unchanged. The interim HARMONi-3 review did not raise safety concerns, which preserves the lead-program thesis [#8-K-2026-04-30].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-04

Base target

$15

p=45%

Bull target

$24

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ASCO plenary overall-survival data from HARMONi-6
Mid-2026 expansion of combination and Phase III development breadth
The April 30 company update kept the core ivonescimab timeline intact: ASCO OS data on May 31, HARMONi-3 squamous final PFS still in 2H 2026, and the November 14, 2026 PDUFA unchanged.

BearKey bullets

Lead-asset concentration remains extreme; ivonescimab drives the thesis, so weak ASCO, Phase III, or FDA outcomes could re-rate the equity sharply lower.
Program breadth is expanding across multiple trials and collaborations, which raises execution complexity, enrollment risk, and spending needs before any U.S.
approval-derived revenue arrives.

WatchKey bullets

HARMONi-3 squamous final PFS in 2H 2026 after interim continuation

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $15 (p=45%)

Bull/Bear spread: +74% / -35%

Vs latest close: Bull +74% · Base +9% · Bear -35%

Scenario probabilities

Bull Target: $24 (p=30%)Base Target: $15 (p=45%)Bear Target: $9 (p=25%)

Commentary

Headline flow is active and mostly company-driven, but the tone still looks more like milestone monitoring than thesis confirmation. The April 30 update preserved major catalysts yet did not deliver a decisive de-risking event, and the May 1 anchor close of $16.115 still sits far below the packet's median analyst target. Deterministic priors remain negative across 5-, 20-, 60-, and 120-day horizons despite strong evidence quality, so the setup stays cautious until ASCO and later Phase III/FDA checkpoints resolve.

As of 2026-05-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ASCO plenary overall-survival data from HARMONi-6
Mid-2026 expansion of combination and Phase III development breadth

Scenarios

Bull Target (Scenario probability)

$24 / p=30% prob

Base Target (Scenario probability)

$15 / p=45% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Price $14 as of 2026-07-17

Nearest Scenario: Base (∆ 9%)

Targets vs latest close: Bull +74% · Base +9% · Bear -35%

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
HARMONi-3 squamous final PFS in 2H 2026 after interim continuation
The April 30 update said the Independent Data Monitoring Committee recommended HARMONi-3 squamous continue as planned at the interim PFS look, with no safety concerns noted and final PFS data still expected in the second half of 2026; that keeps the program alive but removes the possibility that the interim itself would be the de-risking event [#8-K-2026-04-30].
Prob 70.00% • Move 24.00% • Priced-in 50.00%
EVENT2026-11-14
U.S. PDUFA for ivonescimab on November 14, 2026
Summit reiterated that the FDA accepted the BLA for ivonescimab plus chemotherapy in post-TKI EGFR-mutated non-squamous NSCLC and set a November 14, 2026 PDUFA date, which remains the clearest U.S. commercialization gate for the lead asset [#10-Q-2026-04-30].
Prob 60.00% • Move 35.00% • Priced-in 58.00%

Short-term Catalysts

Next few weeks

ASCO plenary overall-survival data from HARMONi-6
2026-05-31
Summit said overall-survival data from Akeso-sponsored Phase III HARMONi-6 will be presented as a late-breaking plenary at ASCO on May 31, 2026, creating a near-term readthrough for ivonescimab efficacy in first-line squamous NSCLC even though the study was run in China and generated by Akeso [#8-K-2026-04-30].
Prob 80% • Move 16% • Priced-in 45%

Long-term Catalysts

Months to a year

Mid-2026 expansion of combination and Phase III development breadth
2026-07-15
Summit said the initial GSK-combination study is expected to begin dosing patients in mid-2026, ILLUMINE enrollment is expected to begin in Q2 2026, and the RevMed collaboration already began enrolling in Q1 2026; these milestones broaden the ivonescimab platform story but are still support points rather than decisive value inflections [#8-K-2026-04-30].
Prob 72% • Move 10% • Priced-in 38%

Risks

Lead-asset concentration remains extreme; ivonescimab drives the thesis, so weak ASCO, Phase III, or FDA outcomes could re-rate the equity sharply lower.
Program breadth is expanding across multiple trials and collaborations, which raises execution complexity, enrollment risk, and spending needs before any U.S. approval-derived revenue arrives.
Quarterly cash use stayed heavy, with net cash used in operations of $122.3 million in Q1 2026 and aggregate cash, cash equivalents, and short-term investments down to $598.7 million, limiting room for major setbacks if timelines slip [#8-K-2026-04-30].
The HARMONi-3 squamous interim did not produce an early de-risking win; investors now wait for the harder final PFS readout in the second half of 2026 [#8-K-2026-04-30].

Peers

Symbol	Summary
MRK	Direct NSCLC immuno-oncology comparator because Summit's HARMONi-3 is designed against pembrolizumab plus chemotherapy, while Summit's 10-K also identifies Merck's sacituzumab tirumotecan among Phase III competitive candidates in first-line NSCLC [#10-K-2026-02-23].
AZN	Relevant direct competitive readthrough because Summit's 10-K names AstraZeneca's volrustomig, rilvegostomig, and datopotamab deruxtecan as NSCLC competitive candidates, including Phase III activity in settings near HARMONi-3 [#10-K-2026-02-23].
PFE	More direct than generic market-cap biotech peers because Summit's 10-K cites Pfizer's sigvotatug vedotin among antibody-drug-conjugate competitors with Phase III activity in NSCLC, making it useful for tracking investor appetite for alternative lung-cancer mechanisms [#10-K-2026-02-23].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-04